Centurion Prim

Informazioni principali

  • Nome commerciale:
  • Centurion Prim
  • Forma farmaceutica:
  • EC concentrato emulsionato
  • Utilizzare per:
  • Piante
  • Tipo di medicina:
  • Agrochimico

Documenti

  • per i professionisti:
  • Il foglio illustrativo per questo prodotto non è al momento disponibile, é possibile inviare una richiesta al nostro Servizio Clienti ed essere avvisati nel momento in cui è disponibile sulla nostra piattaforma.


    Richiedi il foglio illustrativo per i professionisti.

Localizzazione

  • Disponibile in:
  • Centurion Prim
    Svizzera
  • Lingua:
  • italiano

Informazioni terapeutiche

  • Gruppo terapeutico:
  • Erbicida

Altre informazioni

Status

  • Fonte:
  • UFAG - Ufficio federale dell'agricoltura. OFAG - Office fédéral de l'agriculture. BLW - Bundesamt für Landwirtschaft.
  • Numero dell'autorizzazione:
  • W-6258
  • Ultimo aggiornamento:
  • 18-11-2018

Foglio illustrativo: composizione, posologia, indicazioni, interazioni, gravidanza, allattamento, effetti indesiderati, controindicazioni

Denominazione commerciale: Centurion Prim

Elenco dei prodotti fitosanitari (stato: 06.11.2018)

Categoria di prodotti:

Titolare dell'autorizzazione:

Numero federale di omologazione:

Erbicida

Stähler Suisse SA

W-6258

Principio:

Tenore:

Codice di formulazione:

Principio attivo: Clethodim 12.9 % 120 g/l

EC concentrato emulsionato

Applicazioni

A

Coltura

Agente

patogeno/Efficacia

Dosaggio

Restrizioni

B Fragola

Gramigna

Dose: 2 l/ha

Applicazione: Prima della fioritura

o dopo il raccolto

B Fragola

Monocotiledoni annuali

(malerbe).

Dose: 1 l/ha

Applicazione: Prima della fioritura

o dopo il raccolto

O Frutta a granelli

Gramigna

Dose: 2 l/ha

O Frutta a granelli

Monocotiledoni annuali

(malerbe).

Dose: 1 l/ha

W Vite

Gramigna

Dose: 2 l/ha

W Vite

Monocotiledoni annuali

(malerbe).

Dose: 1 l/ha

G Carote

Gramigna

Dose: 2 l/ha

Termine d'attesa: 8 Settimane

Applicazione: In post-emergenza.

G Carote

Monocotiledoni annuali

(malerbe).

Dose: 1 l/ha

Termine d'attesa: 8 Settimane

Applicazione: In post-emergenza.

G Cavoli a testa

Gramigna

Dose: 2 l/ha

Termine d'attesa: 4 Settimane

Applicazione: In post-emergenza.

G Cavoli a testa

Monocotiledoni annuali

(malerbe).

Dose: 1 l/ha

Termine d'attesa: 4 Settimane

A

Coltura

Agente

patogeno/Efficacia

Dosaggio

Restrizioni

Applicazione: In post-emergenza.

Cipolle

Pomodori

Gramigna

Dose: 2 l/ha

Termine d'attesa: 8 Settimane

Applicazione: In post-emergenza.

Cipolle

Pomodori

Monocotiledoni annuali

(malerbe).

Dose: 1 l/ha

Termine d'attesa: 8 Settimane

Applicazione: In post-emergenza.

G Fagioli

Gramigna

Dose: 2 l/ha

Applicazione: In post-emergenza.

G Fagioli

Monocotiledoni annuali

(malerbe).

Dose: 1 l/ha

Applicazione: In post-emergenza.

G Piselli senza baccello

Monocotiledoni annuali

(malerbe).

Dose: 1 l/ha

G Porro

Gramigna

Dose: 2 l/ha

Termine d'attesa: 4 Settimane

Applicazione: In post-emergenza.

G Porro

Monocotiledoni annuali

(malerbe).

Dose: 1 l/ha

Termine d'attesa: 4 Settimane

Applicazione: In post-emergenza.

Barbabietole da foraggio e

da zucchero

Patate

Gramigna

Dose: 2 l/ha

Barbabietole da foraggio e

da zucchero

Patate

Monocotiledoni annuali

(malerbe).

Dose: 1 l/ha

Colza

Girasole

Pisello proteico

Soia

Monocotiledoni annuali

(malerbe).

Dose: 1 l/ha

Girasole

Gramigna

Dose: 2 l/ha

Lino

Gramigna

Dose: 2 l/ha

Lino

Monocotiledoni annuali

(malerbe).

Dose: 1 l/ha

Restrizioni e osservazioni:

Al massimo 1 trattamento per anno.

Ultimo trattamento: prima della fioritura.

Caratterizzazione di pericolo:

Tenere fuori dalla portata dei bambini.

EUH 208 Contiene [denominazione della sostanza sensibilizzante]. Può provocare una reazione

allergica.

EUH 401 Per evitare rischi per la salute umana e per l'ambiente, seguire le istruzioni per l'uso.

H304 Può essere letale in caso di ingestione e di penetrazione nelle vie respiratorie.

H336 Può provocare sonnolenza o vertigini.

H411 Tossico per gli organismi acquatici con effetti di lunga durata.

SP 1 Non contaminare l'acqua con il prodotto o il suo imballaggio.

SPe 2 Onde proteggere le acque sotterranee evitare i trattamenti nelle zone di protezione delle

acque sotterranee (S 2 e S 3).

Avvertenza:

Pericolo

Simboli e indicazioni di pericolo:

Identificatore chiave

GHS07

GHS08

GHS09

Simbolo

Indicazione di pericolo Attenzione pericolo

Pericoloso per la

salute

Pericoloso per l'ambiente acquatico

In caso di dubbio valgono soltanto i documenti originali dell'omologazione. La menzione di un prodotto,

principio attivo o di una ditta non rappresenta alcuna raccomandazione.

10-1-2019


Stakeholder workshop on support to quality development in early access approaches, such as PRIME and Breakthrough Therapies, European Medicines Agency, London, UK, from 26/11/2018 to 26/11/2018

Stakeholder workshop on support to quality development in early access approaches, such as PRIME and Breakthrough Therapies, European Medicines Agency, London, UK, from 26/11/2018 to 26/11/2018

Stakeholder workshop on support to quality development in early access approaches, such as PRIME and Breakthrough Therapies, European Medicines Agency, London, UK, from 26/11/2018 to 26/11/2018

Europe - EMA - European Medicines Agency

20-11-2018

FDA approves first treatment specifically for patients with rare and life-threatening type of immune disease

FDA approves first treatment specifically for patients with rare and life-threatening type of immune disease

The FDA approved Gamifant (emapalumab-lzsg) for the treatment of pediatric (newborn and above) and adult patients with primary hemophagocytic lymphohistiocytosis (HLH) who have refractory, recurrent or progressive disease or intolerance with conventional HLH therapy. This FDA approval is the first for a drug specifically for HLH.

FDA - U.S. Food and Drug Administration

8-11-2018

Statement from FDA Commissioner Scott Gottlieb, M.D., and Janet Woodcock, M.D., director of the Center for Drug Evaluation and Research, on approval of OTC Primatene Mist to treat mild asthma

Statement from FDA Commissioner Scott Gottlieb, M.D., and Janet Woodcock, M.D., director of the Center for Drug Evaluation and Research, on approval of OTC Primatene Mist to treat mild asthma

FDA approves new version of OTC Primatene Mist inhaler to treat mild, intermittent asthma for people who have been diagnosed with asthma by their physician

FDA - U.S. Food and Drug Administration

26-10-2018

Multi-country outbreak of Listeria monocytogenes sequence type 8 infections linked to consumption of salmon products

Multi-country outbreak of Listeria monocytogenes sequence type 8 infections linked to consumption of salmon products

Published on: Thu, 25 Oct 2018 00:00:00 +0200 A multi-country outbreak of 12 listeriosis cases caused by Listeria monocytogenes sequence type (ST) 8 has been identified through whole genome sequencing (WGS) analysis in three EU/EEA countries: Denmark (6 cases), Germany (5) and France (1). Four of these cases have died due to or with the disease. It is likely that the extent of this outbreak has been underestimated since the outbreak was identified through sequencing and only a subset of the EU/EEA count...

Europe - EFSA - European Food Safety Authority Publications

31-8-2018

Alcon Announces Voluntary Global Market Withdrawal of CyPass Micro-Stent for Surgical Glaucoma

Alcon Announces Voluntary Global Market Withdrawal of CyPass Micro-Stent for Surgical Glaucoma

Reflecting its uncompromising commitment to patient safety, Alcon today announced an immediate, voluntary market withdrawal of the CyPass Micro-Stent from the global market. In addition, Alcon advises surgeons to immediately cease further implantation with the CyPass Micro-Stent and to return any unused devices to Alcon. This decision and corresponding recommendation is based on an analysis of five-year post-surgery data from the COMPASS-XT long-term safety study. The US Food and Drug Administration (FD...

FDA - U.S. Food and Drug Administration

29-8-2018

Scientific Opinion on the state of the art of Toxicokinetic/Toxicodynamic (TKTD) effect models for regulatory risk assessment of pesticides for aquatic organisms

Scientific Opinion on the state of the art of Toxicokinetic/Toxicodynamic (TKTD) effect models for regulatory risk assessment of pesticides for aquatic organisms

Published on: Thu, 23 Aug 2018 00:00:00 +0200 Following a request from EFSA, the Panel on Plant Protection Products and their Residues (PPR) developed an opinion on the state of the art of Toxicokinetic/Toxicodynamic (TKTD) models and their use in prospective environmental risk assessment (ERA) for pesticides and aquatic organisms. TKTD models are species‐ and compound‐specific and can be used to predict (sub)lethal effects of pesticides under untested (time‐variable) exposure conditions. Three differen...

Europe - EFSA - European Food Safety Authority Publications

21-8-2018

Companies can now apply for authorisation to produce cannabis bulk and cannabis primary products

Companies can now apply for authorisation to produce cannabis bulk and cannabis primary products

On 1 July 2018, a new executive order entered into force which gives companies the possibility of cultivating medicinal cannabis and producing cannabis bulk and cannabis primary products from Danish-grown cannabis.

Danish Medicines Agency

24-7-2018

FDA Advises Vets of Percorten™-V Shortage and Alternative Drug Option for Treatment of Canine Addison’s Disease

FDA Advises Vets of Percorten™-V Shortage and Alternative Drug Option for Treatment of Canine Addison’s Disease

FDA is aware of a shortage of Percorten™-V (desoxycorticosterone pivalate injectable suspension), which is approved for use as replacement therapy for mineralocorticoid deficit in dogs with primary adrenocortical insufficiency, more commonly known as Addison’s Disease.

FDA - U.S. Food and Drug Administration

13-7-2018

Scientific guideline:  Guideline on good pharmacogenomic practice - First version, adopted

Scientific guideline: Guideline on good pharmacogenomic practice - First version, adopted

This guideline provides recommendations for the conduct of genomic studies in relation to medical therapy in order to provide high quality information on the impact of genomic variability on drug response. Primary focus is on the analysis of genomic germline DNA. The analysis of somatic DNA and genomic biomarkers for cancer treatment is not being discussed and might be developed as an Annex or in separate guidance.

Europe - EFSA - European Food Safety Authority EFSA Journal

21-6-2018

Now Health Group Inc. Recalls Select Now Real Food® Zesty Sprouting Mix Because of Possible Health Risk

Now Health Group Inc. Recalls Select Now Real Food® Zesty Sprouting Mix Because of Possible Health Risk

NOW Health Group, Inc. (NOW), of Bloomingdale, Illinois, is recalling its NOW Real Food® Zesty Sprouting Mix – Product Code 7271, Lot #3031259 and Lot #3038165 – because its primary ingredient, Crimson Clover Seeds, has the potential to be contaminated with Salmonella, an organism which can cause serious and sometimes fatal infections in young children, frail or elderly people, and others with weakened immune systems. Healthy persons infected with Salmonella often experience fever, diarrhea (which may b...

FDA - U.S. Food and Drug Administration

10-5-2018

Nota Informativa Importante su XGEVA (denosumab) (16/05/2018)

Nota Informativa Importante su XGEVA (denosumab) (16/05/2018)

L'Agenzia Italiana del Farmaco rende disponibili nuove e importanti informazioni sul potenziale rischio di insorgenza di nuovo tumore maligno primitivo in seguito al trattamento con XGEVA® (denosumab).

Italia - AIFA - Agenzia Italiana del Farmaco

6-4-2018

Two lots of the epilepsy drug Primidone recalled because of high levels of lead, which may pose serious health risks

Two lots of the epilepsy drug Primidone recalled because of high levels of lead, which may pose serious health risks

Health Canada is advising Canadians that AA Pharma Inc. is voluntarily recalling two lots of Primidone tablets because they contain high levels of lead. The company has indicated that only the lots identified below are affected by this issue.

Health Canada

19-12-2018


Recommendations on eligibility to PRIME scheme -  Adopted at the CHMP meeting of 10-13 December 2018

Recommendations on eligibility to PRIME scheme - Adopted at the CHMP meeting of 10-13 December 2018

Recommendations on eligibility to PRIME scheme - Adopted at the CHMP meeting of 10-13 December 2018

Europe - EMA - European Medicines Agency

18-9-2018

 Third industry stakeholder platform on research and development support, European Medicines Agency, London, UK, From: 18-May-2018, To: 18-May-2018

Third industry stakeholder platform on research and development support, European Medicines Agency, London, UK, From: 18-May-2018, To: 18-May-2018

This third meeting between regulators and representatives of industry stakeholder organisations addresses all areas of product-development support, including scientific advice, specifics for paediatric and orphan medicines and support for innovation. The meeting focuses on the implementation of the orphan notice, ‘histology-independent indications’ in the context of orphan designations, the upcoming rollout of a new tool for orphan designation applications, digital technology proposals in medicine develo...

Europe - EMA - European Medicines Agency

13-9-2018

 European Medicines Agency stakeholder interaction on the development of medicinal products for chronic non-infectious liver diseases (PBC, PSC, NASH), European Medicines Agency, London, UK, From: 03-Dec-2018, To: 03-Dec-2018

European Medicines Agency stakeholder interaction on the development of medicinal products for chronic non-infectious liver diseases (PBC, PSC, NASH), European Medicines Agency, London, UK, From: 03-Dec-2018, To: 03-Dec-2018

This workshop on the development of medicines for chronic non-infectious liver diseases, including primary biliary cholangitis, primary sclerosing cholangitis and nonalcoholic steatohepatitis, provides a platform for discussion on appropriate endpoints including validation of surrogate endpoints/biomarkers, suitable study populations, potentially adequate trial designs and the specific challenges with paediatric medicine development. The workshop will support the drafting of a reflection paper on regul...

Europe - EMA - European Medicines Agency